View Older Stories View More Recent Stories

Sep 2, 2021 07:00AM Syndax Announces Participation at Three Upcoming Investor Conferences
Aug 9, 2021 04:01PM Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update
Aug 2, 2021 07:00AM Syndax to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021
Jun 28, 2021 07:06AM Syndax Pharmaceuticals (SNDX) SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias
Jun 28, 2021 07:00AM SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias
Jun 3, 2021 07:00AM Syndax Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference
May 13, 2021 07:00AM Syndax Announces Participation in Cowen 2nd Annual Virtual Oncology Innovation Summit
May 4, 2021 07:00AM Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021
Apr 5, 2021 04:21PM Vyant Bio (VYNT) Announces Newly Appointed Board of Directors
Apr 5, 2021 04:20PM Vyant Bio Announces Newly Appointed Board of Directors
Mar 1, 2021 07:00AM Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021
Feb 24, 2021 07:00AM Syndax Announces Participation at Two Upcoming Investor Conferences
Dec 18, 2020 07:00AM Syndax Pharmaceuticals To Be Added to the NASDAQ Biotechnology Index
Dec 6, 2020 12:30PM Syndax Pharmaceuticals Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD
Nov 30, 2020 07:00AM Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts
Nov 11, 2020 07:00AM Syndax Announces Presentation at Stifel 2020 Virtual Healthcare Conference
Nov 4, 2020 04:05PM Syndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual Meeting
Nov 2, 2020 04:05PM Syndax Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Business Update
Oct 26, 2020 07:00AM Syndax to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 2, 2020
Sep 2, 2020 07:00AM Syndax Announces Participation at Three Upcoming Investor Conferences
Aug 6, 2020 04:05PM Syndax Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update
Aug 3, 2020 07:00AM Syndax Announces Participation in BTIG Virtual Biotechnology Conference
Jul 30, 2020 07:00AM Syndax to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020
Jul 7, 2020 07:03AM Syndax Pharmaceuticals (SNDX) Announces Daphne Karydas as CFO
Jul 7, 2020 07:00AM Syndax Pharmaceuticals Appoints Daphne Karydas as Chief Financial Officer
May 21, 2020 04:36PM Syndax Pharmaceuticals (SNDX) Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer Did Not Achieve Primary Endpoint
May 21, 2020 04:35PM ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer
May 7, 2020 04:05PM Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update
Apr 30, 2020 07:00AM Syndax to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 7, 2020
Apr 27, 2020 04:53PM Syndax Pharmaceuticals (SNDX) Announces Preclinical Profie & Initial Ph. 1 Data Demonstrating Clinical Activity of Menin Inhibitor SNDX-5613
Apr 27, 2020 04:05PM Syndax Pharmaceuticals Announces Preclinical Profile and Initial Phase 1 Data Demonstrating Clinical Activity of Menin Inhibitor SNDX-5613 in Adults with Relapsed/Refractory Acute Leukemias
Apr 14, 2020 07:00AM Syndax Pharmaceuticals Announces Three Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting
Mar 3, 2020 04:05PM Syndax Pharmaceuticals Reports Fourth Quarter 2019 Financial Results and Provides Clinical and Business Update
Feb 25, 2020 07:00AM Syndax to Announce Fourth Quarter and Year-end 2019 Financial Results and Host Conference Call and Webcast on March 3, 2020
Feb 18, 2020 07:00AM Syndax Announces Participation at Two Upcoming Investor Conferences
Jan 31, 2020 07:00AM Syndax Announces $35.0 Million Offering of Common Stock and Enters Term Sheet for Loan with Hercules Capital for up to $30 Million
Jan 30, 2020 02:13PM Syndax (SNDX) Announces Science Magazine Published Results from Preclinical Study on Activity of Menin-MLL Inhibition for Treatment of NPM1 AML
Jan 30, 2020 02:11PM Science Magazine Publishes Results from Preclinical Study on the Activity of Menin-MLL Inhibition for the Treatment of NPM1 Acute Myeloid Leukemia
Jan 10, 2020 04:08PM Syndax Pharmaceuticals (SNDX) Highlights 2020 Clinical and Corporate Outlook
Jan 10, 2020 04:05PM Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook
Dec 10, 2019 07:02AM Syndax Pharmaceuticals (SNDX) Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of cGVHD
Dec 10, 2019 07:00AM Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease
Dec 9, 2019 04:39PM Syndax Pharmaceuticals (SNDX) Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias
Dec 9, 2019 04:05PM Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias
Nov 7, 2019 04:05PM Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update
Nov 6, 2019 07:25AM Syndax Pharmaceuticals (SNDX) Reports First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613
Nov 6, 2019 07:00AM Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias
Oct 31, 2019 07:00AM Syndax to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7, 2019
Aug 28, 2019 07:00AM Syndax Announces Participation at Four Upcoming Investor Conferences
Aug 7, 2019 04:05PM Syndax Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Clinical and Business Update
View More Recent Stories View Older Stories